These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29335942)

  • 21. Lipoprotein(a) and atherosclerotic disease in insulin-dependent diabetic patients with declining glomerular filtration rate.
    Earle KA; Mattock M; Morocutti A; Aravanitis D; Viberti GC
    Diabet Med; 1996 Dec; 13(12):1071-2. PubMed ID: 8973890
    [No Abstract]   [Full Text] [Related]  

  • 22. [Lipoprotein(a) as a cardiovascular risk factor].
    van Lennep JE; Mulder MT
    Ned Tijdschr Geneeskd; 2011; 155(42):A3582. PubMed ID: 22027461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins.
    Haines CJ; Chung TK; Masarei JR; Tomlinson B; Lau JT
    Atherosclerosis; 1996 Jan; 119(2):215-22. PubMed ID: 8808498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein(a): an emerging cardiovascular risk factor.
    Lippi G; Guidi G
    Crit Rev Clin Lab Sci; 2003 Feb; 40(1):1-42. PubMed ID: 12627747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)
    Marcovina SM; Viney NJ; Hughes SG; Xia S; Witztum JL; Tsimikas S
    J Clin Lipidol; 2018; 12(1):122-129.e2. PubMed ID: 29174389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editorial Lp(a) - the underestimated cardiovascular risk factor.
    Mellwig KP
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):1. PubMed ID: 28236286
    [No Abstract]   [Full Text] [Related]  

  • 27. The impact of molecular medicine upon early cardiovascular drug development.
    Lunnon MW; Braddock M
    Br J Clin Pharmacol; 2000 Jul; 50(1):1-8. PubMed ID: 10886110
    [No Abstract]   [Full Text] [Related]  

  • 28. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
    Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Leebmann J; Lehmacher W; Kamstrup PR; Nordestgaard BG; Maerz W; Noureen A; Schmidt K; Kronenberg F; Heibges A; Klingel R;
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.
    Ridker PM; Stampfer MJ; Rifai N
    JAMA; 2001 May; 285(19):2481-5. PubMed ID: 11368701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
    Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.
    Scipione CA; Koschinsky ML; Boffa MB
    Crit Rev Clin Lab Sci; 2018 Jan; 55(1):33-54. PubMed ID: 29262744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The significance of lipoprotein(a) in assessment of risk for atherosclerosis].
    Kullich W; Machreich K
    Wien Med Wochenschr; 1994; 144(17):407-11. PubMed ID: 7839688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical significance of and treatment options for increased lipoprotein(a)].
    Zsíros N; Paragh G; Harangi M
    Orv Hetil; 2014 Apr; 155(16):607-14. PubMed ID: 24733102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
    Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
    Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.
    Hohenstein B; Tselmin S; Bornstein SR; Julius U
    Atheroscler Suppl; 2017 Nov; 30():28-32. PubMed ID: 29096851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Not Available].
    Kronenberg F
    Praxis (Bern 1994); 2017 Aug; 106(17):949-954. PubMed ID: 28830318
    [No Abstract]   [Full Text] [Related]  

  • 38. [The smoking gun of cardiovascular diseases? The great interest in Lp(a)-lipoprotein].
    Dahlén GH
    Lakartidningen; 1993 Jan; 90(4):259-62. PubMed ID: 8433604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lipoprotein(a) and atheromatous disease of epiaortic arterial trunks in the very old].
    Spada RS; Ferri R; Mangiafico RA; Roccasalva G; Toscano G; Di Cataldo V; Santonocito M
    Minerva Cardioangiol; 1998 Sep; 46(9):306-7. PubMed ID: 10021855
    [No Abstract]   [Full Text] [Related]  

  • 40. [Is there a relationship between sex, age, Lp(a) blood levels, lipid values, and atherosclerotic carotid lesions?].
    Postorino G; Altavilla R; Fantozzi G; Provenzano B; Cappelli R; Forconi S
    Minerva Med; 1996 Sep; 87(9):379-83. PubMed ID: 8975176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.